A Three-Year Trial of Atromid Therapy in Exudative Diabetic Retinopathy

Duncan, L. J. P.; Cullen, J F; Ireland, John; Nolan, J; Clarke, B F; Oliver, M.F.

doi:10.2337/diab.17.7.458

Cited by 98 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We were also able to show that, over a 3 year period, clofibrate caused regression of exudative lipid-rich lesions as demonstrated by retinal photography [15]. We related this to the substantial triglyceride-lowering effect of clofibrate.…”

Section: Diabetic Retinopathymentioning

confidence: 52%

The clofibrate saga: a retrospective commentary

Oliver¹

2012

Brit J Clinical Pharma

View full text Add to dashboard Cite

IntroductionAfter many years of study clofibrate, the first of the fibrates, seemed in the 1960s, to be an effective means of lowering raised plasma cholesterol. It provided an opportunity for examining the key question of whether reduction of plasma cholesterol might lead to reduction in the incidence of coronary heart disease (CHD). While small secondary prevention trials looked promising, a large primary prevention trial (the WHO trial) carried out over 5.3 years on 15 745 men aged 30-59 years provided contradictory results with reduction in nonfatal myocardial infarction, less hypertension, no change in coronary mortality but an increase in non-cardiovascular mortality. Clofibrate also increased gall stone formation and the need for cholecystectomies. Clofibrate was not an appropriate drug to recommend for population control of CHD. It did, however, usher in other fibrates and foreshadowed successful statin trials.

show abstract

Section: Diabetic Retinopathymentioning

confidence: 52%

The clofibrate saga: a retrospective commentary

Oliver¹

2012

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…These small trials of either clofibrate or atromid in exudative maculopathy have suggested that a reduction in macular hard exudates could be achieved, but with little improvement in visual acuity. 43,44 Of note, however, is that the visual acuity of the patients in these trials was poor at the outset, and hence a significant improvement with lipid lowering therapy may not be expected. A more recent German pilot study used etofibrate in patients with type 2 diabetes and type 2b hyperlipoproteinaemia with diabetic maculopathy.…”

Section: Lipid Lowering Therapy In Exudative Maculopathymentioning

confidence: 99%

The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

Chowdhury

Hopkins

Dodson

et al. 2002

Eye

View full text Add to dashboard Cite

The treatment for diabetic maculopathy is laser photocoagulation of the pigment epithelium. With the advent of systemic lipid lowering therapy over the last decade, there may be potential for medical therapy also. There is some anecdotal evidence of the effect of lipid lowering agents (particularly statins) in reducing exudate, and a number of studies have shown that lipid lowering therapy may reduce macular exudates, but numbers in these trials are small. A randomised controlled trial is now required to investigate whether the use of systemic lipid lowering therapy is of benefit in patients with exudative maculopathy, even in the absence of dyslipidaemia.

show abstract

“…They showed beneficial effects on retinal and macular hard exudates. However, the improvement in retinal hard exudates was not associated with any significant improvement in visual acuity or reduction in retinal hemorrhages [67][68][69]. In a pilot study of 11 subjects with hyperlipoproteinemia and mild to moderate background DR treated with etofibrate for a period of 6 months, regression of hard exudates was observed in 7 out of 10 patients [70].…”

Section: Fibratesmentioning

confidence: 99%

Dyslipidemia and Diabetic Retinopathy

Chang

2013

Rev Diabet Stud

103

View full text Add to dashboard Cite

■ AbstractDiabetic retinopathy (DR) is one of the major microvascular complications of diabetes. In developed countries, it is the most common cause of preventable blindness in diabetic adults. Dyslipidemia, a major systemic disorder, is one of the most important risk factors for cardiovascular disease. Patients with diabetes have an increased risk of suffering from dyslipidemia concurrently. The aim of this article is to review the association between diabetic retinopathy (DR) and traditional/nontraditional lipid markers, possible mechanisms involving lipid metabolism and diabetic retinopathy, and the effect of lipid-lowering therapies on diabetic retinopathy. For traditional lipid markers, evidence is available that total cholesterol and low-density lipoprotein cholesterol are associated with the presence of hard exudates in patients with DR. The study of nontraditional lipid markers is advancing only in recently years. The severity of DR is inversely associated with apolipoprotein A1 (ApoA1), whereas ApoB and the ApoB-to-ApoA1 ratio are positively associated with DR. The role of lipid-lowering medication is to work as adjunctive therapy for better control of diabetes-related complications including DR.

show abstract

A Three-Year Trial of Atromid Therapy in Exudative Diabetic Retinopathy

Cited by 98 publications

References 14 publications

The clofibrate saga: a retrospective commentary

The clofibrate saga: a retrospective commentary

The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?

Dyslipidemia and Diabetic Retinopathy

Contact Info

Product

Resources

About